Cargando…

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients

BACKGROUND: Phosphatidylinositol 3-kinase delta (PI3Kδ) and Janus-activated kinases (JAK) are both novel anti-inflammatory targets in asthma that affect lymphocyte activation. We have investigated the anti-inflammatory effects of PI3Kδ and JAK inhibition on cytokine release from asthma bronchoalveol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Southworth, Thomas, Plumb, Jonathan, Gupta, Vandana, Pearson, James, Ramis, Isabel, Lehner, Martin D., Miralpeix, Montserrat, Singh, Dave
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051065/ https://www.ncbi.nlm.nih.gov/pubmed/27716212 http://dx.doi.org/10.1186/s12931-016-0436-2

Ejemplares similares

PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge
por: Southworth, Thomas, et al.
Publicado: (2018)

The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro
por: Milara, Javier, et al.
Publicado: (2022)

Investigation into the Role of PI3K and JAK3 Kinase Inhibitors in Murine Models of Asthma
por: Wagh, Akshaya D., et al.
Publicado: (2017)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
por: Gunerka, Paweł, et al.
Publicado: (2020)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies
por: Haselmayer, Philipp, et al.
Publicado: (2014)

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
por: Kim, Joo Hyun, et al.
Publicado: (2018)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor
por: Cai, Yu, et al.
Publicado: (2020)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases
por: Helmer, Eric, et al.
Publicado: (2017)

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
por: Choong, Meng Ling, et al.
Publicado: (2013)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

CRTH2 antagonists in asthma: current perspectives
por: Singh, Dave, et al.
Publicado: (2017)

Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury
por: Bilancio, Antonio, et al.
Publicado: (2017)

Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ
por: Cevey, Ágata C., et al.
Publicado: (2021)

Effect of the circadian cycle in Late Asthmatic Response (LAR). Comparison between two allergic asthma models in rats and mice
por: Otal, Raquel, et al.
Publicado: (2013)

The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors
por: Berndt, Alex, et al.
Publicado: (2010)

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
por: Gadi, Deepti, et al.
Publicado: (2023)

PI3Kδ过度活化综合征一例
Publicado: (2021)

PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma
por: Bi, Jing, et al.
Publicado: (2020)

PI3Kδ inhibition prevents IL33, ILC2s and inflammatory eosinophils in persistent airway inflammation
por: Uddin, Sorif, et al.
Publicado: (2021)

An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial
por: Cahn, Anthony, et al.
Publicado: (2021)

Tuning the Biological Activity of PI3Kδ Inhibitor by the Introduction of a Fluorine Atom Using the Computational Workflow
por: Pietruś, Wojciech, et al.
Publicado: (2023)

Epithelial PI3K-δ Promotes House Dust Mite-Induced Allergic Asthma in NLRP3 Inflammasome-Dependent and -Independent Manners
por: Kim, So Ri, et al.
Publicado: (2020)

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
por: Wolf, Alexandra, et al.
Publicado: (2013)

User's guide to JAK inhibitors in inflammatory bowel disease
por: Spiewak, Ted A., et al.
Publicado: (2022)

The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
por: Caiazzo, Giuseppina, et al.
Publicado: (2023)

PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
por: Putz, Eva Maria, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_q6utc5i8gga6q1pimgup3f50hq